NextCure Inc. is a biopharmaceutical company focused on discovering and developing novel immunomedicines to treat cancer and other immune-related diseases. The company was founded in 2015 and is headquartered in Beltsville, Maryland, USA. The company is listed on the Nasdaq stock exchange under the ticker symbol "NXTC."
NextCure's primary goal is to leverage its expertise in the field of immunology to identify and target novel immune checkpoints that regulate immune responses in cancer patients. By understanding the underlying biology of these checkpoints, NextCure aims to develop innovative therapies that can modulate the immune system and improve patient outcomes.
NextCure's approach involves utilizing its proprietary Functional Antibody Screening Technology (FAST) platform, which enables the identification of novel immunomodulatory targets. This platform combines high-throughput screening with extensive biological and clinical data to identify potential therapeutic targets.
NC318 is a monoclonal antibody that targets Siglec-15, an immune checkpoint receptor expressed on various tumor-infiltrating immune cells and is NextCure's leading drug. By blocking Siglec-15, NC318 aims to enhance anti-tumor immune responses and potentially improve the effectiveness of existing cancer immunotherapies.
NextCure is also actively engaged in expanding its pipeline and exploring additional targets for the development of immunomedicines. The company collaborates with academic institutions, research organizations, and industry partners to further advance its understanding of immune checkpoint biology and identify novel therapeutic targets.